Health Care & Life Sciences » Biotechnology | Uni-Bio Science Group Ltd.

Uni-Bio Science Group Ltd. | Income Statement

Fiscal year is January-December. All values HKD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
83,333.00
122,390.40
123,364.00
146,489.00
156,477.00
135,258
Cost of Goods Sold (COGS) incl. D&A
79,462.00
84,623.00
52,323.00
50,472.00
53,105.00
22,736
Gross Income
3,871.00
37,767.40
71,041.00
96,017.00
103,372.00
112,522
SG&A Expense
66,311.00
136,183.00
121,141.00
154,438.00
187,811.00
237,498
EBIT
62,440.00
98,415.60
-
58,421.00
84,439.00
124,976
Unusual Expense
803.00
524.00
7,468.00
1,003.00
198,953.00
19,042
Non Operating Income/Expense
1,998.00
8,014.70
2,429.00
2,723.00
3,224.00
1,379
Interest Expense
7,670.00
-
-
497.00
177.00
247
Pretax Income
68,263.00
54,161.20
52,186.00
53,820.00
278,297.00
138,433
Income Tax
1,045.00
1,854.70
2,569.00
1,907.00
1,012.00
134
Equity in Affiliates
-
562.70
5,044.00
-
-
-
Consolidated Net Income
69,308.00
56,578.50
59,799.00
55,727.00
279,309.00
138,567
Net Income
69,308.00
56,578.50
59,799.00
55,727.00
279,309.00
138,567
Net Income After Extraordinaries
69,308.00
56,578.50
59,799.00
55,727.00
279,309.00
138,567
Net Income Available to Common
69,308.00
56,578.50
59,799.00
55,727.00
279,309.00
138,567
EPS (Basic)
0.04
0.01
0.01
0.01
0.05
0.02
Basic Shares Outstanding
1,661,566.60
4,865,201.00
4,997,990.00
5,091,770.00
5,426,650.00
6,175,911
EPS (Diluted)
0.04
0.01
0.01
0.01
0.05
0.02
Diluted Shares Outstanding
1,661,566.60
4,865,201.00
4,997,990.00
5,091,770.00
5,426,650.00
6,175,911
EBITDA
21.00
34,272.60
18,385.00
30,574.00
54,183.00
104,056
Non-Operating Interest Income
155.00
390.70
2,953.00
1,372.00
744.00
1,078
Equity in Affiliates (Pretax)
497.00
-
-
-
-
-

About Uni-Bio Science Group

View Profile
Address
Unit 502, 5/F
Hong Kong
Hong Kong
Employees -
Website http://www.uni-bioscience.com
Updated 07/08/2019
Uni-Bio Science Group Ltd. is an investment holding company with interests in pharmaceutical research and development. It operates through the following segments: Manufacture and Sale of in-house chemical pharmaceutical products; Manufacture and sale of in-house biological pharmaceutical products; Industrialization of in-house biological pipeline; and Third Party pharmaceutical products. The company was founded in 2001 and is headquartered in Hong Kong.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.